Outlook Therapeutics, Inc. (OTLK) has 7 SEC Form 4 insider filings on record in the last 90 days. That includes 4 insider purchases totalling $2.6M. Most recent filing: Sept. 2, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 2, 2026 filed Sept. 1, 2026 | Lundquist Kevin Michael Chief Financial Officer | $0 | 500,000 | 0% | No | |
|
|
||||||
| Aug. 14, 2026 | Jahr Robert Charles Chief Executive Officer | $0 | 303,030 | New | No | |
|
|
||||||
| Aug. 14, 2026 filed Aug. 12, 2026 | Sukhtian Ghiath M. Director | +$2,499,999 | 5,050,504 | New | No | |
|
|
||||||
| Aug. 14, 2026 | KENYON LAWRENCE A Chief Financial Officer | $0 | 202,020 | New | No | |
|
|
||||||
| July 29, 2026 | Sukhtian Faisal Ghiath Director | +$99,996 | 95,398 | +76% | No | |
|
|
||||||
Showing the 5 most recent of 7 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free